Back
ESC Premium Access

Tolerability and safety of sacubitril/valsartan in high-risk subgroups

Session: Poster Session 1 - Chronic heart failure – Treatment
Topic: Pharmacotherapy
Speaker: Doctor J. Neiva (Viana do Castelo, PT)
Event: ESC Congress 2018

Congress Presentation

Add to my library

Like

About the speaker

Doctor Joana Neiva

ULSAM - Hospital de Santa Luzia, Viana do Castelo (Portugal)
0 follower

7 more presentations in this session

Early commencement of tolvaptan therapy improves clinical outcomes in heart failure patients with preserved function of renal vasopressin V2 receptors

Speaker: Doctor T. Noto (Sapporo, JP)

Access
Abstract
Like
Thumbnail

Research into the effect of sodium-glucose linked transporter inhibition in left ventricular remodelling in patients with heart failure and diabetes mellitus.

Speaker: Professor C. Lang (Dundee, GB)

Access
Abstract
Like
Thumbnail

Diminished response to statin therapy predicts future occurrence of heart failure in patients with acute myocardial infarction

Speaker: Doctor K. Tsuda (Takatsuki, JP)

Access
Abstract
Like
Thumbnail

Titration patterns and clinical characteristics of patients prescribed sacubitril/valsartan in the primary care and cardiology settings in germany

Speaker: Associate Professor R. Wachter (Leipzig, DE)

Access
Abstract
Slides
Like
Thumbnail

Characteristics of heart failure patients treated with Sacubitril - Valsartan in Europe. Results from ARIADNE

Speaker: Professor U. Zeymer (Ludwigshafen, DE)

Access
Abstract
Like
Thumbnail

Access the full session

Poster Session 1 - Chronic heart failure – Treatment

Speakers: Doctor J. Neiva, Doctor T. Noto, Professor C. Lang, Doctor K. Tsuda, Associate Professor R. Wachter...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources